Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2012

View Archived Issues

Negative findings reported from LEAP study of CO-101

Novel biguanide inhibits cell proliferation and cyst growth of human ADPKD cells

Vertex presents in vitro results for a novel CFTR corrector

Nerviano Medical Sciences patents novel protein kinase inhibitors

GlaxoSmithKline discloses new TRPV1 antagonists

French team synthesizes novel ALK tyrosine kinase receptor inhibitors

New S1P1 receptor agonists presented by French and Indian researchers

Bayer Intellectual Property divulges novel GCS activators

Laboratoire Biodim prepares new anti-HIV agents

Promising phase I results presented for myrcludex B

Immunomic Therapeutics begins phase I study of JRC-LAMP-vax vaccine

Phase III pancreatic cancer study of Abraxane meets primary endpoint

Astellas partners with Japanese universities for antiprotozoan drugs

FDA approves Prezista 800-mg tablets for the treatment of HIV

Novartis files supplemental NDA for Neoral in Japan

China's State Food and Drug Administration approves first-in-human trial of APX-003

RedHill Biopharma concludes pre-NDA meeting with FDA for RHB-103

PATH's Drug Development program to advance antidiarrheal candidate

Phase I/IIa study of RPh-201 in chronic vegetative patients begins in Israel

FDA advisory committee schedules review of Zohydro

Advanced Cell Technology reports interim clinical data on hESC-derived RPE cells

Interim results presented for a peptide-based cancer vaccine

U.S. screening begins for new phase Ib study of PRTX-100

First patient receives NiCord stem cell transplant in pilot study

Health Canada approves Cymbalta for pain associated with osteoarthritis of the knee

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...